Hematopoietic cell transplantation: five decades of progress.

Animals; Graft vs Host Disease; HLA Antigens/immunology/metabolism; Hematologic Diseases/therapy; Hematopoietic Stem Cell Transplantation/history; History, 20th Century; History, 21st Century; Humans; Transplantation Chimera; Transplantation Conditioning; Transplantation Immunology; Transplantation, Homologous/history

Abstract :

[en] During the past 50 years, the role of allogeneic hematopoietic cell transplantation (HCT) has changed from a desperate therapeutic maneuver plagued by apparently insurmountable complications to a curative treatment modality for thousands of patients with hematologic diseases. Now, cure rates following human leukocyte antigen (HLA) allogeneic HCT with matched siblings exceed 85% for some otherwise lethal diseases, such as chronic myeloid leukemia, aplastic anemia, or thalassemia. In addition, the recent development of non-myeloablative conditioning and stem cell transplantation has opened the way to include elderly patients with a wide variety of hematologic malignancies. Further progress in adoptive transfer of T cell populations with relative tumor specificity would make the transplant procedure more effective and would extend the use of allogeneic HCT for treatment of non-hematopoietic malignancies.

Disciplines :

Hematology

Author, co-author :

Baron, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > GIGA-R : Hématologie - Département des sciences cliniques

Storb, Rainer

Little, Marie-Terese

Language :

English

Title :

Hematopoietic cell transplantation: five decades of progress.

Publication date :

2003

Journal title :

Archives of Medical Research

ISSN :

0188-4409

Publisher :

Elsevier Science, New York, United States - New York

Volume :

Issue :

Pages :

528-44

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 23 June 2013

Statistics

Number of views

166 (1 by ULiège)

Number of downloads

379 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Owen R.D. Immunogenetic consequences between vascular anastomoses between bovine twins. Science. 102:1945;400-402.
Billingham R.E., Brent L., Medawar P.B. "Actively acquired tolerance" of foreign cells. Nature. 172:1953;603-606.
Burnet M. The clonal selection theory of acquired immunity. 1959;Cambridge University Press, London.
Woodruff M.F.A. The transplantation of tissues and organs. 1960;Charles C Thomas, Springfield, IL, USA.
Brent L. A history of transplantation immunology. 1997;Academic Press, San Diego, CA, USA.
van Bekkum D.W., de Vries M.J. Radiation chimaeras. 1967;Logos Press Ltd, London.
Jacobson L.O., Simmons E.L., Marks E.K., Eldredge J.H. Recovery from radiation injury. Science. 113:1951;510-511.
Lorenz E., Uphoff D., Reid T.R., Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst. 12:1951;197-201.
Jacobson L.O., Simmons E.L., Marks E.K., Gaston E.O., Robson M.J., Eldredge J.H. Further studies on recovery from radiation injury. J Lab Clin Med. 37:1951;683-697.
Barnes D.W.H., Loutit J.F. What is the recovery factor in spleen? Nucleonics. 12:1954;68-71.
Main J.M., Prehn R.T. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst. 15:1955;1023-1029.
Nowell P.C., Cole L.J., Habermeyer J.G., Roan P.L. Growth and continued function of rat marrow cells in x-radiated mice. Cancer Res. 16:1956;258-261.
Ford C.E., Hamerton J.L., Barnes D.W.H., Loutit J.F. Cytological identification of radiation-chimaeras. Nature. 177:1956;452-454.
Trentin J.J. Mortality and skin transplantability in x-irradiated mice receiving isologous or heterologous bone marrow. Proc Soc Exp Biol Med. 92:1956;688-693.
Vos O., Davids J.A.G., Weyzen W.W.H., van Bekkum D.W. Evidence for cellular hypothesis in radiation protection by bone marrow cells. Acta Physiol Pharmacol Neerland. 4:1956;482-486.
Lindsley D.L., Odell T.T., Tausche F.G. Implantation of functional erythropoietic elements following total-body irradiation. Proc Soc Exp Biol Med. 90:1955;512-515.
Makinodan T. Circulating rat cells in lethally irradiated mice protected with rat bone marrow. Proc Soc Exp Biol Med. 92:1956;174-179.
Barnes D.W.H., Corp M.J., Loutit J.F., Neal F.E. Treatment of murine leukaemia with x-rays and homologous bone marrow. Preliminary communication. Br Med J. 2:1956;626-627.
van Bekkum D.W., Vos O., Weyzen W.W.H. Homo- et hété rogreffe tissues hématopoiétiques chez la souris. Rev d'Hémat. 11:1956;477-485.
Billingham R.E., Brent L. Quantitative studies on tissue transplantation immunity IV. Induction of tolerance in newborn mice and studies on the phenomenon of runt disease . Philos Trans R Soc Lond B Biol Sci. 242:1959;477-481.
Uphoff D.E. Genetic factors influencing irradiation protection by bone marrow I. The F1 hybrid effect . J Natl Cancer Inst. 19:1957;123-125.
Uphoff D.E. Alteration of homograft reaction by A-methopterin in lethally irradiated mice treated with homologous marrow. Proc Soc Exp Biol Med. 99:1958;651-653.
Thomas E.D., Lochte H.L. Jr., Lu W.C., Ferrebee J.W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 257:1957;491-496.
Mathé G., Amiel J.L., Schwarzenberg L., Catton A., Schneider M. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. 25:1965;1525-1531.
Andrews G.A. Criticality accidents in Vinca, Yugoslavia, and Oak Ridge, Tennessee. Am J Roentgenol Radium Ther Nucl Med. 93:1965;56-74.
McGovern J.J. Jr., Russel P.S., Atkins L., Webster E.W. Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. N Engl J Med. 260:1959;675-683.
Beilby J.O.W., Cade I.S., Jeliffe A.M., Parkin D.M., Stewart J.W. Prolonged survival of a bone-marrow graft resulting in a blood group chimera. Br Med J. 1:1960;96-99.
Bortin M.M. A compendium of reported human bone marrow transplants. Transplantation. 9:1970;571-587.
Storb R., Thomas E.D. Graft-versus-host disease in dog and man: the Seattle Experience. Möller G. Immunological Reviews No. 88. 1985;215-238 Munksgaard, Copenhagen, Denmark.
Thomas E.D., Storb R. The development of the scientific foundation of hematopoietic cell transplantation based on animal and human studies. Thomas E.D., Blume K.G., Forman S.J. Hematopoietic cell transplantation. 2nd edition :1999;1-11 Blackwell Science, Boston, MA, USA.
Snell G.D. The Nobel Lectures in Immunology. Lecture for the Nobel Prize for Physiology or Medicine, 1980: Studies in histocompatibility (review). Scand J Immunol. 36:1992;513-526.
Epstein R.B., Storb R., Ragde H., Thomas E.D. Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation. 6:1968;45-58.
Storb R., Epstein R.B., Graham T.C., Thomas E.D. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation. 9:1970;240-246.
Gatti R.A., Meuwissen H.J., Allen H.D., Hong R., Good R.A. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 2:1968;1366-1369.
Thomas E.D., Storb R., Clift R.A., Fefer A., Johnson F.L., Neiman P.E., Lerner K.G., Glucksberg H., Buckner C.D. Bone-marrow transplantation. N Engl J Med. 292:1975;832-843. 895-902.
Thomas E.D., Buckner C.D., Banaji M., Clift R.A., Fefer A., Flournoy N., Goodell B.W., Hickman R.O., Lerner K.G., Neiman P.E., Sale G.E., Sanders J.E., Singer J., Stevens M., Storb R., Weiden P.L. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 49:1977;511-533.
Thomas E.D., Buckner C.D., Clift R.A., Fefer A., Johnson F.L., Neiman P.E., Sale G.E., Sanders J.E., Singer J.W., Shulman H., Storb R., Weiden P.L. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med. 301:1979;597-599.
Thomas E.D., Sanders J.E., Flournoy N., Johnson F.L., Buckner C.D., Clift R.A., Fefer A., Goodell B.W., Storb R., Weiden P.L. Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood. 54:1979;468-476.
Goldman J.M., Apperley J.F., Jones L., Marcus R., Goolden A.W.G., Batchelor R., Hale G., Waldmann H., Reid C.D., Hows J., Gordon-Smith E., Catovsky D., Galton D.A.G. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 314:1986;202-207.
Thomas E.D., Clift R.A., Fefer A., Appelbaum F.R., Beatty P., Bensinger W.I., Buckner C.D., Cheever M.A., Deeg H.J., Doney K., Flournoy N., Greenberg P., Hansen J.A., Martin P., McGuffin R., Ramberg R., Sanders J.E., Singer J., Stewart P., Storb R., Sullivan K., Weiden P.L., Witherspoon R. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 104:1986;155-163.
Thomas E.D., Buckner C.D., Sanders J.E., Papayannopoulou T., Borgna-Pignatti C., De Stefano P., Sullivan K.M., Clift R.A., Storb R. Marrow transplantation for thalassaemia. Lancet. 2:1982;227-229.
Johnson F.L., Look A.T., Gockerman J., Ruggiero M.R., Dalla-Pozza L., Billings F.T. III. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 311:1984;780-783.
Thomas E.D., Bryant J.I., Buckner C.D., Clift R.A., Fefer A., Johnson F.L., Neiman P., Ramberg R.E., Storb R. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1:1972;1310-1313.
Fialkow P.J., Thomas E.D., Bryant J.I., Neiman P.E. Leukaemic transformation of engrafted human marrow cellsin vivo. Lancet. 1:1971;252-255.
Thomas E.D., Clift R.A., Hersman J., Sanders J.E., Stewart P., Buckner C.D., Fefer A., McGuffin R., Smith J.W., Storb R. Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys. 8:1982;817-821.
Santos G.W., Tutschka P.J., Brookmeyer R., Saral R., Beschorner W.E., Bias W.B., Braine H.G., Burns W.H., Elfenbein G.J., Kaizer H., Mellits D., Sensenbrenner L.L., Stuart R.K., Yeager A.M. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 309:1983;1347-1353.
Clift R.A., Buckner C.D., Thomas E.D., Bensinger W.I., Bowden R., Bryant E., Deeg H.J., Doney K.C., Fisher L.D., Hansen J.A., Martin P., McDonald G.B., Sanders J.E., Schoch G., Singer J., Storb R., Sullivan K.M., Witherspoon R.P., Appelbaum F.R. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 84:1994;2036-2043.
Clift R.A., Radich J., Appelbaum F.R., Martin P., Flowers M.E.D., Deeg H.J., Storb R., Thomas E.D. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia (letter to the editor). Blood. 94:1999;3960-3962.
Socié G., Clift R.A., Blaise D., Devergie A., Ringden O., Martin P.J., Remberger M., Deeg H.J., Ruutu T., Michallet M., Sullivan K.M., Chevret S. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of the 4 randomized studies. Blood. 98:2001;3569-3574.
Storb R., Etzioni R., Anasetti C., Appelbaum F.R., Buckner C.D., Bensinger W., Bryant E., Clift R., Deeg H.J., Doney K., Flowers M., Hansen J., Martin P., Pepe M., Sale G., Sanders J., Singer J., Sullivan K.M., Thomas E.D., Witherspoon R.P. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 84:1994;941-949.
Storb R., Blume K.G., O'Donnell M.R., Chauncey T., Forman S.J., Deeg H.J., Hu W.W., Appelbaum F.R., Doney K., Flowers M.E.D., Sanders J., Leisenring W. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant. 7:2001;39-44.
Lucarelli G., Galimberti M., Polchi P., Angelucci E., Baronciani D., Giardini C., Politi P., Durazzi S.M.T., Muretto P., Albertini F. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 322:1990;417-421.
Lucarelli G., Galimberti M., Polchi P., Angelucci E., Baronciani D., Giardini C., Andreani M., Agostinelli F., Albertini F., Clift R.A. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 329:1993;840-844.
Walters M.C., Patience M., Leisenring W., Eckman J.R., Scott J.P., Mentzer W.C., Davies S.C., Ohene-Frempong K., Bernaudin F., Matthews D.C., Storb R., Sullivan K.M. Bone marrow transplantation for sickle cell disease. N Engl J Med. 335:1996;369-376.
Deeg H.J., Storer B., Slattery J.T., Anasetti C., Doney K.C., Hansen J.A., Kiem H.-P., Martin P.J., Petersdorf E., Radich J.P., Sanders J.E., Shulman H.M., Warren E.H., Witherspoon R.P., Bryant E.M., Chauncey T.R., Getzendaner L., Storb R., Appelbaum F.R. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 100:2002;1201-1207.
Bornhäuser M., Storer B., Slattery J.T., Appelbaum F.R., Deeg H.J., Hansen J., Martin P.J., McDonald G.B., Nichols G., Radich J., Woolfrey A., Jenke A., Schleyer E., Thiede C., Ehninger G., Anasetti C. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 102:2003;820-826.
Lochte H.L. Jr., Levy A.S., Guenther D.M., Thomas E.D., Ferrebee J.W. Prevention of delayed foreign marrow reaction in lethally irradiated mice by early administration of methotrexate. Nature. 196:1962;1110-1111.
Storb R., Deeg H.J., Farewell V., Doney K., Appelbaum F., Beatty P., Bensinger W., Buckner C.D., Clift R., Hansen J., Hill R., Longton G., Lum L., Martin P., McGuffin R., Sanders J., Singer J., Stewart P., Sullivan K., Witherspoon R., Thomas E.D. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 68:1986;119-125.
Storb R., Deeg H.J., Whitehead J., Appelbaum F., Beatty P., Bensinger W., Buckner C.D., Clift R., Doney K., Farewell V., Hansen J., Hill R., Lum L., Martin P., McGuffin R., Sanders J., Stewart P., Sullivan K., Witherspoon R., Yee G., Thomas E.D. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 314:1986;729-735.
Storb R., Raff R.F., Appelbaum F.R., Deeg H.J., Fitzsimmons W., Graham T.C., Pepe M., Pettinger M., Sale G., Van Der Jagt R., Schuening F.G. FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-nonidentical donors. Transplantation. 56:1993;800-807.
Nash R.A., Antin J.H., Karanes C., Fay J.W., Avalos B.R., Yeager A.M., Przepiorka D., Davies S., Petersen F.B., Bartels P., Buell D., Fitzsimmons W., Anasetti C., Storb R., Ratanatharathorn V. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 96:2000;2062-2068.
Martin P.J., Hansen J.A., Buckner C.D., Sanders J.E., Deeg H.J., Stewart P., Appelbaum F.R., Clift R., Fefer A., Witherspoon R.P., Kennedy M.S., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 66:1985;664-672.
Marmont A.M., Horowitz M.M., Gale R.P., Sobocinski K., Ash R.C., van Bekkum D.W., Champlin R.E., Dicke K.A., Goldman J.M., Good R.A., Herzig R.H., Hong R., Masaoka T., Rimm A.A., Ringden O., Speck B., Weiner R.S., Bortin M.M. T-cell depletion of HLA-identical transplants in leukemia. Blood. 78:1991;2120-2130.
Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champlin R.E., Gluckman E., Hoffmann R.G., Jacobsen S.J., Marmont A.M., McGlave P.B., Messner H.A., Rimm A.A., Rozman C., Speck B., Tura S., Weiner R.S., Bortin M.M. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med. 108:1988;806-814.
Baron F., Beguin Y. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation (review). Biol Blood Marrow Transplant. 8:2002;351-359.
Speck B., Zwaan F.E., van Rood J.J., Eernisse J.G. Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HLA-A-identical unrelated donor. Transplantation. 16:1973;24-28.
Hansen J.A., Petersdorf E.W. Unrelated donor hematopoietic cell transplantation. Thomas E.D., Blume K.G., Forman S.J. Hematopoietic cell transplantation. 2nd edition :1999;915-928 Blackwell Science, Boston, MA, USA.
Hansen J.A., Gooley T.A., Martin P.J., Appelbaum F., Chauncey T.R., Clift R.A., Petersdorf E.W., Radich J., Sanders J.E., Storb R.F., Sullivan K.M., Anasetti C. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 338:1998;962-968.
Bensinger W.I., Martin P.J., Storer B., Clift R., Forman S.J., Negrin R., Kashyap A., Flowers M.E.D., Lilleby K., Chauncey T.R., Storb R., Appelbaum F.R. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 344:2001;175-181.
Schmitz N., Bacigalupo A., Hasenclever D., Nagler A., Gluckman E., Clark P., Bourquelot P., Greinix H., Frickhofen N., Ringden O., Zander A., Apperley J.F., Gorin C., Borkett K., Schwab G., Goebel M., Russell N.H., Gratwohl A. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 21:1998;995-1003.
Couban S., Simpson D.R., Barnett M.J., Bredeson C., Hubesch L., Howson-Jan K., Shore T.B., Walker I.R., Browett P., Messner H.A., Panzarella T., Lipton J.H., Canadian Bone Marrow Transplant Group. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 100:2002;1525-1531.
Mohty M., Kuentz M., Michallet M., Bourhis J.H., Milpied N., Sutton L., Jouet J.P., Attal M., Bordigoni P., Cahn J.Y., Boiron J.M., Blaise D. Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood. 100:2002;3128-3134.
Flowers M.E.D., Parker P.M., Johnston L.J., Matos A.V.B., Storer B., Bensinger W.I., Storb R., Appelbaum F.R., Forman S.J., Blume K.G., Martin P.J. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 100:2002;415-419.
Gluckman E., Rocha V., Boyer-Chammard A., Locatelli F., Arcese W., Pasquini R., Ortega J., Souillet G., Ferreira E., Laporte J.-P., Fernández M., Chastang C. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 337:1997;373-381.
Kurtzberg J., Laughlin M., Graham M.L., Smith C., Olson J.F., Halperin E.C., Ciocci G., Carrier C., Stevens C.E., Rubinstein P. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 335:1996;157-166.
Rubinstein P., Carrier C., Scaradavou A., Kurtzberg J., Adamson J., Migliaccio A.R., Berkowitz R.L., Cabbad M., Dobrila N.L., Taylor P.E., Rosenfield R.E., Stevens C.E. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 339:1998;1565-1577.
Wagner J.E., Barker J.N., Defor T.E., Baker K.S., Blazar B.R., Eide C., Goldman A., Kersey J., Krivit W., MacMillan M.L., Orchard P.J., Peters C., Weisdorf D.J., Ramsay N.K., Davies S.M. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 100:2002;1611-1618.
Barnes D.W.H., Loutit J.F. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol. 3:1957;241-252.
Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 300:1979;1068-1073.
Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D., the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 304:1981;1529-1533.
Sullivan K.M., Weiden P.L., Storb R., Witherspoon R.P., Fefer A., Fisher L., Buckner C.D., Anasetti C., Appelbaum F.R., Badger C., Beatty P., Bensinger W., Berenson R., Bigelow C., Cheever M.A., Clift R., Deeg H.J., Doney K., Greenberg P., Hansen J.A., Hill R., Loughran T., Martin P., Neiman P., Petersen F.B., Sanders J., Singer J., Stewart P., Thomas E.D. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 73:1989;1720-1728.
Maraninchi D., Gluckman E., Blaise D., Guyotat D., Rio B., Pico J.L., Leblond V., Michallet M., Dreyfus F., Ifrah N., Bordigoni A. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 2:1987;175-178.
Gale R.P., Horowitz M.M., Ash R.C., Champlin R.E., Goldman J.M., Rimm A.A., Ringden O., Stone J.A.V., Bortin M.M. Identical twin bone marrow transplants for leukemia. Ann Intern Med. 120:1994;646-652.
Kolb H.J., Mittermüller J., Clemm C.H., Holler G., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462-2465.
Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D., van Rhee F., Mittermueller J., De Witte T., Holler E., Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 86:1995;2041-2050.
Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J., Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 23:1995;1553-1562.
Collins R.H. Jr., Goldstein S., Giralt S., Levine J., Porter D., Drobyski W., Barrett J., Johnson M., Kirk A., Horowitz M., Parker P. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 26:2000;511-516.
Baron F., Beguin Y. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation (review). Transfusion. 40:2000;468-476.
Oettel K.R., Wesly O.H., Albertini M.R., Hank J.A., Iliopolis O., Sosman J.A., Voelkerding K., Wu S.Q., Clark S.S., Sondel P.M. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient. Blood. 83:1994;3390-3402.
Baron F., Turhan A.G., Giron-Michel J., Azzarone B., Bentires-Alj M., Bours V., Bourhis J.H., Chouaib S., Caignard A. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood. 99:2002;2107-2113.
Orsini E., Alyea E.P., Chillemi A., Schlossman R., McLaughlin S., Canning C., Soiffer R.J., Anderson K.C., Ritz J. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant. 6:2000;375-386.
Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy (review). Immunol Rev. 157:1997;125-140.
Riddell S.R., Greenberg P.D. Adoptive immunotherapy with antigen-specific T cells. Thomas E.D., Blume K.G., Forman S.J. Hematopoietic cell transplantation. 2nd edition :1999;327-341 Blackwell Science, Boston, MA, USA.
Molina A.J., Storb R.F. Hematopoietic stem cell transplantation in older adults. Rowe J.M., Lazarus H.M., Carella A.M. Handbook of bone marrow transplantation. 1st ed. 2000;111-137 Martin Dunitz, Ltd, London.
Slavin S., Nagler A., Naparstek E., Kapelushnik Y., Aker M., Cividalli G., Varadi G., Kirschbaum M., Ackerstein A., Samuel S., Amar A., Brautbar C., Ben-Tal O., Eldor A., Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 91:1998;756-763.
Giralt S., Estey E., Albitar M., van Besien K., Rondón G., Anderlini P., O'Brien S., Khouri I., Gajewski J., Mehra R., Claxton D., Andersson B., Beran M., Przepiorka D., Koller C., Kornblau S., Körbling M., Keating M., Kantarjian H., Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 89:1997;4531-4536.
Khouri I.F., Keating M., Körbling M., Przepiorka D., Anderlini P., O'Brien S., Giralt S., Ippoliti C., von Wolff B., Gajewski J., Donato M., Claxton D., Ueno N., Andersson B., Gee A., Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 16:1998;2817-2824.
Spitzer T.R., McAfee S., Sackstein R., Colby C., Toh H.C., Multani P., Saidman S., Weymouth D.W., Preffer F., Poliquin C., Foley A., Cox B., Andrews D., Sachs D.H., Sykes M. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant. 6:2000;309-320.
McSweeney P.A., Niederwieser D., Shizuru J.A., Sandmaier B.M., Molina A.J., Maloney D.G., Chauncey T.R., Gooley T.A., Hegenbart U., Nash R.A., Radich J., Wagner J.L., Minor S., Appelbaum F.R., Bensinger W.I., Bryant E., Flowers M.E.D., Georges G.E., Grumet F.C., Kiem H.-P., Torok-Storb B., Yu C., Blume K.G., Storb R.F. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 97:2001;3390-3400.
Sykes M., Preffer F., McAfee S., Saidman S.L., Weymouth D., Andrews D.M., Colby C., Sackstein R., Sachs D.H., Spitzer T.R. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 353:1999;1755-1759.
Childs R., Chernoff A., Contentin N., Bahceci E., Schrump D., Leitman S., Read E.J., Tisdale J., Dunbar C., Linehan W.M., Young N.S., Barrett A.J. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 343:2000;750-758.
Childs R., Clave E., Contentin N., Jayasekera D., Hensel N., Leitman S., Read E.J., Carter C., Bahceci E., Young N.S., Barrett A.J. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 94:1999;3234-3241.
Carella A.M., Champlin R., Slavin S., McSweeney P., Storb R. Mini-allografts: ongoing trials in humans (editorial). Bone Marrow Transplant. 25:2000;345-350.
Storb R., Yu C., Wagner J.L., Deeg H.J., Nash R.A., Kiem H.-P., Leisenring W., Shulman H. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 89:1997;3048-3054.
Storb R., Yu C., Barnett T., Wagner J.L., Deeg H.J., Nash R.A., Kiem H.-P., McSweeney P., Seidel K., Georges G., Zaucha J.M. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood. 94:1999;1131-1136.
Storb R., Yu C., Zaucha J.M., Deeg H.J., Georges G., Kiem H.-P., Nash R.A., McSweeney P.A., Wagner J.L. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood. 94:1999;2523-2529.
Yu C., Storb R., Mathey B., Deeg H.J., Schuening F.G., Graham T.C., Seidel K., Burnett R., Wagner J.L., Shulman H., Sandmaier B.M. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood. 86:1995;4376-4381.
Niederwieser D., Maris M., Shizuru J.A., Petersdorf E., Hegenbart U., Sandmaier B.M., Maloney D.G., Storer B., Lange T., Chauncey T., Deininger M., Pönisch W., Anasetti C., Woolfrey A., Little M.-T., Blume K.G., McSweeney P.A., Storb R.F. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 101:2003;1620-1629.
Feinstein L.C., Sandmaier B.M., Maloney D.G., Maris M.B., Gooley T.A., Chauncey T.R., Hegenbart U., McSweeney P.A., Stuart M.J., Forman S.J., Agura E.A., Pulsipher M.A., Blume K.G., Niederwieser D.W., Storb R.F. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant. 9:2003;266-272.
Feinstein L.C., Sandmaier B.M., Hegenbart U., McSweeney P.A., Maloney D.G., Gooley T.A., Maris M.B., Chauncey T.R., Bruno B., Appelbaum F.R., Niederwieser D.W., Storb R.F. Non-myeloablative allografting from human leukocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol. 120:2003;281-288.
Maris M.B., Niederwieser D., Sandmaier B.M., Storer B., Stuart M., Maloney D., Petersdorf E., McSweeney P., Pulsipher M., Woolfrey A., Chauncey T., Agura E., Heimfeld S., Slattery J., Hegenbart U., Anasetti C., Blume K., Storb R. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 102:2003;2021-2030.
Hogan W.J., Little M.-T., Zellmer E., Friedetzky A., Diaconescu R., Gisburne S., Lee R., Kuhr C., Storb R. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant. 9:2003;489-495.
Storb R. Allogeneic hematopoietic stem cell transplantation - yesterday, today, and tomorrow. Exp Hematol. 31:2003;1-10.
Weissinger F., Sandmaier B.M., Maloney D.G., Bensinger W.I., Gooley T., Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood. 98:2001;3584-3588.
Junghanss C., Boeckh M., Carter R.A., Sandmaier B.M., Maris M.B., Maloney D.G., Chauncey T., McSweeney P.A., Little M.-T., Corey L., Storb R. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 99:2002;1978-1985.
Junghanss C., Marr K.A., Carter R.A., Sandmaier B.M., Maris M.B., Maloney D.G., Chauncey T., McSweeney P.A., Storb R. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 8:2002;512-520.
Mielcarek M., Martin P.J., Leisenring W., Flowers M.E.D., Maloney D.G., Sandmaier B.M., Maris M.B., Storb R. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 102:2003;756-762.
Woolfrey A.E., Nash R.A., Sanders J.E., Ochs H.D., Thomson B., Storb R. A nonmyeloablative regimen for induction of multi-lineage hematopoietic mixed donor-host chimerism in nonmalignant disorders (abstract). Blood. 98:(Part 1):2000;784a.
Bethge W.A., Wilbur D.S., Storb R., Hamlin D.K., Santos E.B., Brechbiel M.W., Fisher D.R., Sandmaier B.M. Selective T-cell ablation with bismuth-213 labelled anti-TCR as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood. 101:2003;5068-5075.
Zaucha J.M., Zellmer E., Georges G., Little M.-T., Storb R., Storer B., Torok-Storb B. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant. 7:2001;613-619.
Zaucha J.M., Yu C., Zellmer E., Takatu A., Junghanss C., Little M.-T., Storb R. Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. Biol Blood Marrow Transplant. 7:2001;513-516.
Marijt W.A., Heemskerk M.H., Kloosterboer F.M., Goulmy E., Kester M.G., van der Hoorn M.A., van Luxemburg-Heys S.A., Hoogeboom M., Mutis T., Drijfhout J.W., van Rood J.J., Willemze R., Falkenburg J.H. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA. 100:2003;2742-2747.
Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., Davis M.M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 6:2000;1018-1023.
Gao L., Xue S.A., Hasserjian R., Cotter F., Kaeda J., Goldman J.M., Dazzi F., Stauss H.J. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation. 75:2003;1429-1436.
Baron F., Frere P., Baudoux E., Sautois B., Fillet G., Beguin Y. Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. Haematologica. 88:2003;479-480.
Hentschke P., Barkholt L., Uzunel M., Mattsson J., Wersall P., Pisa P., Martola J., Albiin N., Wernerson A., Soderberg M., Remberger M., Thorne A., Ringden O. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant. 31:2003;253-261.
Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C.T., Gaasenbeek M., Angelo M., Reich M., Pinkus G.S., Ray T.S., Koval M.A., Last K.W., Norton A., Lister T.A., Mesirov J., Neuberg D.S., Lander E.S., Aster J.C., Golub T.R. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 8:2002;68-74.
Storb R., Raff R.F., Appelbaum F.R., Schuening F.W., Sandmaier B.M., Graham T.C., Thomas E.D. What radiation dose for DLA-identical canine marrow grafts? Blood. 72:1988;1300-1304.